Pathophysiological roles of microvascular alterations in pulmonary inflammatory diseases: Possible implications of tumor necrosis factor-alpha and CXC chemokines

International Journal of COPD

Volumn 3, Issue 4, 2008, Pages 619-627

  Orihara, Kanami ^a   Matsuda, Akio ^a  

^a NATIONAL RESEARCH INSTITUTE FOR CHILD HEALTH AND DEVELOPMENT   (Japan)

Author keywords

Asthma; COPD; Corticosteroid; CXC chemokines; Pulmonary microvessels; TNF

Indexed keywords

ALPHA CHEMOKINE; CHEMOKINE RECEPTOR CXCR3; CORTICOSTEROID; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; INTERCELLULAR ADHESION MOLECULE 1; INTERCELLULAR ADHESION MOLECULE 1 ANTIBODY; INTERLEUKIN 8; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 2;

ANGIOGENESIS; ASTHMA; CD4+ T LYMPHOCYTE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CORTICOSTEROID THERAPY; CYTOKINE RELEASE; DRUG TREATMENT FAILURE; EMPHYSEMA; ENDOTHELIUM CELL; FORCED EXPIRATORY VOLUME; GENE EXPRESSION REGULATION; GENE FUNCTION; GENE OVEREXPRESSION; GENE TARGETING; HUMAN; LEUKOCYTE ACTIVATION; LEUKOCYTE ADHERENCE; LUNG BLOOD VESSEL; MICROVASCULARIZATION; NONHUMAN; REVIEW; UPREGULATION; VASCULAR ENDOTHELIUM;

ADRENAL CORTEX HORMONES; ANIMALS; ASTHMA; CHEMOKINES, CXC; HUMANS; LUNG; MICROCIRCULATION; MICROVESSELS; PULMONARY CIRCULATION; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SEVERITY OF ILLNESS INDEX; TUMOR NECROSIS FACTOR-ALPHA; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 60249091058     PISSN: 11769106     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (78)

1. Aaron SD, Angel JB, Lunau M, et al. 2001. Granulocyte inflammatory markers and airway infection during acute exacerbation of chronic obstructive pulmonary disease. Am J Respir Crit Care Med, 163:349-55.
2. Abdel-Rahman AM, el-Sahrigy SA, Bakr SI. 2006. A comparative study of two angiogenic factors: vascular endothelial growth factor and angiogenin in induced sputum from asthmatic children in acute attack. Chest, 129:266-71.
3. Abman SH. 2001. Bronchopulmonary dysplasia:"a vascular hypothesis". Am J Respir Crit Care Med, 164:1755-6.
4. Addison CL, Daniel TO, Burdick MD, et al. 2000. The CXC chemokine receptor 2, CXCR2, is the putative receptor for ELR+ CXC chemokine-induced angiogenic activity. J Immunol, 165:5269-77.
5. Asai K, Kanazawa H, Kamoi H, et al. 2003. Increased levels of vascular endothelial growth factor in induced sputum in asthmatic patients. Clin Exp Allergy, 33:595-9.
6. Asai K, Kanazawa H, Otani K, et al. 2002. Imbalance between vascular endothelial growth factor and endostatin levels in induced sputum from asthmatic subjects. J Allergy Clin Immunol, 110:571-5.
7. Barnes PJ. 2003. Chronic obstructive pulmonary disease * 12:New treatments for COPD. Thorax, 58:803-8.
8. Barnes PJ. 2007. New molecular targets for the treatment of neutrophilic diseases. J Allergy Clin Immunol, 119:1055-62.
9. Barnes PJ. 2008. Immunology of asthma and chronic obstructive pulmonary disease. Nat Rev Immunol, 8:183-92.
10. Barnes PJ, Pedersen S, Busse WW. 1998. Efficacy and safety of inhaled corticosteroids. New developments. Am J Respir Crit Care Med, 157:S1-53.
11. Bentley AM, Hamid Q, Robinson DS, et al. 1996. Prednisolone treatment in asthma. Reduction in the numbers of eosinophils, T cells, tryptase-only positive mast cells, and modulation of IL-4, IL-5, and interferon-gamma cytokine gene expression within the bronchial mucosa. Am J Respir Crit Care Med, 153:551-6.
12. Berry MA, Hargadon B, Shelley M, et al. 2006. Evidence of a role of tumor necrosis factor alpha in refractory asthma. N Engl J Med, 354:697-708.
13. Broide DH, Sullivan S, Gifford T, et al. 1998. Inhibition of pulmonary eosinophilia in P-selectin- and ICAM-1-deficient mice. Am J Respir Cell Mol Biol, 18:218-25.
14. Burdick MD, Murray LA, Keane MP, et al. 2005. CXCL11 attenuates bleomycin-induced pulmonary fibrosis via inhibition of vascular remodeling. Am J Respir Crit Care Med, 171:261-8.
15. Busse WW, Lemanske RF Jr. 2001. Asthma. N Engl J Med, 344:350-62.
16. Carlos TM, Harlan JM. 1994. Leukocyte-endothelial adhesion molecules. Blood, 84:2068-101.
17. Chetta A, Zanini A, Foresi A, et al. 2003. Vascular component of airway remodeling in asthma is reduced by high dose of fluticasone. Am J Respir Crit Care Med, 167:751-7.
18. Chetta A, Zanini A, Foresi A, et al. 2005. Vascular endothelial growth factor up-regulation and bronchial wall remodelling in asthma. Clin Exp Allergy, 35:1437-42.
19. Chung KF. 2001. Cytokines in chronic obstructive pulmonary disease. Eur Respir, J (Suppl 34):50s-59s.
20. Cotran R, Pober JS. 1990. Cytokine-endothelial interactions in inflammation, immunity, and vascular injury. J Am Soc Nephrol, 1:225-35.
21. Di Stefano A, Capelli A, Lusuardi M, et al. 1998. Severity of airflow limitation is associated with severity of airway inflammation in smokers. Am J Respir Crit Care Med, 158:1277-85.
22. Di Stefano A, Capelli A, Lusuardi M, et al. 2001. Decreased T lymphocyte infiltration in bronchial biopsies of subjects with severe chronic obstructive pulmonary disease. Clin Exp Allergy, 31:893-902.
23. Feldmann M, Maini RN. 2003. Lasker Clinical Medical Research Award. TNF defined as a therapeutic target for rheumatoid arthritis and other autoimmune diseases. Nat Med, 9:1245-50.
24. Feltis BN, Wignarajah D, Reid DW, et al. 2007. Effects of inhaled fluticasone on angiogenesis and vascular endothelial growth factor in asthma. Thorax, 62:314-9.
25. Ferrara N, Gerber HP, LeCouter J. 2003. The biology of VEGF and its receptors. Nat Med, 9:669-76.
26. Grashoff WF, Sont JK, Sterk PJ, et al. 1997. Chronic obstructive pulmonary disease:role of bronchiolar mast cells and macrophages. Am J Pathol, 151:1785-90.
27. Grumelli S, Corry DB, Song LZ, et al. 2004. An immune basis for lung parenchymal destruction in chronic obstructive pulmonary disease and emphysema. PLoS Med, 1:e8.
28. Hacievliyagil SS, Gunen H, Mutlu LC, et al. 2006. Association between cytokines in induced sputum and severity of chronic obstructive pulmonary disease. Respir Med, 100:846-54.
29. Hardaker EL, Bacon AM, Carlson K, et al. 2004. Regulation of TNF-alpha- and IFN-gamma-induced CXCL10 expression:participation of the airway smooth muscle in the pulmonary inflammatory response in chronic obstructive pulmonary disease. Faseb J, 18:191-3.
30. Hatfield CA, Brashler JR, Winterrowd GE, et al. 1997. Intercellular adhesion molecule-1-deficient mice have antibody responses but impaired leukocyte recruitment. Am J Physiol, 273:L513-23.
31. Hay DW, Sarau HM. 2001. Interleukin-8 receptor antagonists in pulmonary diseases. Curr Opin Pharmacol, 1:242-7.
32. Heidemann J, Ogawa H, Dwinell MB, et al. 2003. Angiogenic effects of interleukin 8 (CXCL8) in human intestinal microvascular endothelial cells are mediated by CXCR2. J Biol Chem, 278:8508-15.
33. Hogg JC, Chu F, Utokaparch S, et al. 2004. The nature of small-airway obstruction in chronic obstructive pulmonary disease. N Engl J Med, 350:2645-53.
34. Holgate ST, Holloway J, Wilson S, et al. 2006. Understanding the pathophysiology of severe asthma to generate new therapeutic opportunities. J Allergy Clin Immunol, 117:496-506.
35. Hoshino M, Nakamura Y, Hamid QA. 2001a. Gene expression of vascular endothelial growth factor and its receptors and angiogenesis in bronchial asthma. J Allergy Clin Immunol, 107:1034-8.
36. Hoshino M, Takahashi M, Aoike N. 2001b. Expression of vascular endothelial growth factor, basic fibroblast growth factor, and angiogenin immunoreactivity in asthmatic airways and its relationship to angiogenesis. J Allergy Clin Immunol, 107:295-301.
37. Howarth PH, Babu KS, Arshad HS, et al. 2005. Tumour necrosis factor (TNFalpha) as a novel therapeutic target in symptomatic corticosteroid dependent asthma. Thorax, 60:1012-8.
38. Issa R, Xie S, Khorasani N, et al. 2007. Corticosteroid inhibition of growth-related oncogene protein-alpha via mitogen-activated kinase phosphatase-1 in airway smooth muscle cells. J Immunol, 178:7366-75.
39. Jakkula M, Le Cras TD, Gebb S, et al. 2000. Inhibition of angiogenesis decreases alveolarization in the developing rat lung. Am J Physiol Lung Cell Mol Physiol, 279:L600-7.
40. Jeffery PK. 2000. Comparison of the structural and inflammatory features of COPD and asthma. Giles F. Filley Lecture. Chest, 117 (Suppl 1):251S-60S.
41. Johnston SL, Pattemore PK, Sanderson G, et al. 1995. Community study of role of viral infections in exacerbations of asthma in 9-11 year old children. Bmj, 310:1225-9.
42. Kamath AV, Pavord ID, Ruparelia PR, et al. 2005. Is the neutrophil the key effector cell in severe asthma? Thorax, 60:529-30.
43. Kanazawa H, Asai K, Hirata K, et al. 2003. Possible effects of vascular endothelial growth factor in the pathogenesis of chronic obstructive pulmonary disease. Am J Med, 114:354-8.
44. Kanazawa H, Hirata K, Yoshikawa J. 2002. Involvement of vascular endothelial growth factor in exercise induced bronchoconstriction in asthmatic patients. Thorax, 57:885-8.
45. Kasahara Y, Tuder RM, Taraseviciene-Stewart L, et al. 2000. Inhibition of VEGF receptors causes lung cell apoptosis and emphysema. J Clin Invest, 106:1311-9.
46. Kelly M, Hwang JM, Kubes P. 2007. Modulating leukocyte recruitment in inflammation. J Allergy Clin Immunol, 120:3-10.
47. Laitinen LA, Laitinen A, Heino M, et al. 1991. Eosinophilie airway inflammation during exacerbation of asthma and its treatment with inhaled corticosteroid. Am Rev Respir Dis, 143:423-7.
48. Lasagni L, Francalanci M, Annunziato F, et al. 2003. An alternatively spliced variant of CXCR3 mediates the inhibition of endothelial cell growth induced by IP-10, Mig, and I-TAC, and acts as functional receptor for platelet factor 4. J Exp Med, 197:1537-49.
49. Lee CG, Link H, Baluk P, et al. 2004. Vascular endothelial growth factor (VEGF) induces remodeling and enhances TH2-mediated sensitization and inflammation in the lung. Nat Med, 10:1095-103.
50. Lee YC, Lee K. 2001. Vascular endothelial growth factor in patients with acute asthma. J Allergy Clin Immunol, 107:1106.
51. Liebow AA. 1959. Pulmonary emphysema with special reference to vascular changes. Am Rev Respir, Dis 80:67-93.
52. Majori M, Corradi M, Caminati A, et al. 1999. Predominant TH1 cytokine pattern in peripheral blood from subjects with chronic obstructive pulmonary disease. J Allergy Clin Immunol, 103:458-62.
53. Mann BS, Chung KF. 2006. Blood neutrophil activation markers in severe asthma: lack of inhibition by prednisolone therapy. Respir Res, 7:59.
54. Marx N, Mach F, Sauty A, et al. 2000. Peroxisome prohiferator-activated receptor-gamma activators inhibit IFN-gamma-induced expression of the T cell-active CXC chemokines IP-10, Mig, and I-TAC in human endothelial cells. J Immunol, 164:6503-8.
55. Matsuda A, Fukuda S, Matsumoto K, et al. 2008a. Th1/Th2 cytokines reciprocally regulate in vitro pulmonary angiogenesis via CXC chemokine synthesis. Am J Respir Cell Mol Biol, 38:168-75.
56. Matsuda A, Orihara K, Fukuda S, et al. 2008b. Corticosteroid enhances TNF-alpha-mediated leukocyte adhesion to pulmonary microvascular endothelial cells. Allergy, (in press). DOI:10.1111/ j.1398-9995.2008.01775.
57. Nagase T, Fukuchi Y, Matsuse T, et al. 1995. Antagonism of ICAM-1 attenuates airway and tissue responses to antigen in sensitized rats. Am J Respir Crit Care Med, 151:1244-9.
58. Newton R, Holden NS, Catley MC, et al. 2007. Repression of inflammatory gene expression in human pulmonary epithelial cells by small-molecule IkappaB kinase inhibitors. J Pharmacol Exp Ther, 321:734-42.
59. Nicholson KG, Kent J, Ireland DC. 1993. Respiratory viruses and exacerbations of asthma in adults. Bmj, 307:982-6.
60. Panina-Bordignon P, Papi A, Mariani M, et al. 2001. The C-C chemokine receptors CCR4 and CCR8 identify airway T cells of allergen-challenged atopic asthmatics. J Clin Invest, 107:1357-64.
61. Pesci A, Balbi B, Majori M, et al. 1998. Inflammatory cells and mediators in bronchial lavage of patients with chronic obstructive pulmonary disease. Eur Respir J, 12:380-6.
62. Rennard SI, Fogarty C, Kelsen S, et al. 2007. The safety and efficacy of infliximab in moderate to severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med, 175:926-34.
63. Risau W. 1997. Mechanisms of angiogenesis. Nature 386:671-4.
64. Rohde G, Wiethege A, Borg I, et al. 2003. Respiratory viruses in exacerbations of chronic obstructive pulmonary disease requiring hospitalisation: a case-control study. Thorax, 58:37-42.
65. Saetta M, Mariani M, Panina-Bordignon P, et al. 2002. Increased expression of the chemokine receptor CXCR3 and its ligand CXCL10 in peripheral airways of smokers with chronic obstructive pulmonary disease. Am J Respir Crit Care Med, 165:1404-9.
66. Sauty A, Dziejman M, Taha RA, et al. 1999. The T cell-specific CXC chemokines IP-10, Mig, and I-TAC are expressed by activated human bronchial epithelial cells. J Immunol, 162:3549-58.
67. Schleimer RP. 1990. Effects of glucocorticosteroids on inflammatory cells relevant to their therapeutic applications in asthma. Am Rev Respir Dis, 141:S59-69.
68. Seemungal TA, Harper-Owen R, Bhowmik A, et al. 2000. Detection of rhinovirus in induced sputum at exacerbation of chronic obstructive pulmonary disease. Eur Respir J, 16:677-83.
69. Senger DR, Van de Water L, Brown LF, et al. 1993. Vascular permeability factor (VPF, VEGF) in tumor biology. Cancer Metastasis Rev, 12:303-24.
70. Silvestri M, Bontempelli M, Giacomelli M, et al. 2006. High serum levels of tumour necrosis factor-alpha and interleukin-8 in severe asthma:markers of systemic inflammation? Clin Exp Allergy, 36:1373-81.
71. Spoelstra FM, Postma DS, Hovenga H, et al. 2000. Budesonide and formoterol inhibit ICAM-1 and VCAM-1 expression of human lung fibroblasts. Eur Respir, J 15:68-74.
72. Staunton DE, Merluzzi VJ, Rothlein R, et al. 1989. A cell adhesion molecule, ICAM-1, is the major surface receptor for rhinoviruses. Cell, 56:849-53.
73. Tanaka H, Yamada G, Saikai T, et al. 2003. Increased airway vascularity in newly diagnosed asthma using a high-magnification bronchovideoscope. Am J Respir Crit Care Med, 168:1495-9.
74. Tillie-Leblond I, de Blic J, Jaubert F, et al. 2008. Airway remodeling is correlated with obstruction in children with severe asthma. Allergy, 63:533-41.
75. Vrugt B, Wilson S, Bron A, et al. 2000. Bronchial angiogenesis in severe glucocorticoid-dependent asthma. Eur Respir J, 15:1014-21.
76. Wilson J. 2000. The bronchial microcirculation in asthma. Clin Exp Allergy, 30 (Suppl 1):51-3.
77. Yancopoulos GD, Davis S, Gale NW, et al. 2000. Vascular-specific growth factors and blood vessel formation. Nature, 407:242-8.
78. Zlotnik A, Yoshie O. 2000. Chemokines:a new classification system and their role in immunity. Immunity, 12:121-7.